Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
03/30/2017
Trade Name:
Orencia
Generic Name or Proper Name (*):
abatacept
Indications Studied:
Treatment of moderately to severely active Polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older
Label Changes Summary:
*Approved for use in pJIA in pediatric patients 2 years and older as monotherapy or concominatly with methotrexate. *For pJIA, Orencia may be administered as an intraveneous infusion in 6 years and older or a subcutaneous injection in 2 years and older. Intraveneous dosing has not been studied in pediatric patients younger than 6 years of age. *Orencia with intravenous administration has not been studied in patients younger than 6 years of age. *Efficacy of Orencia for subcutaneous injection in children 2 to 17 years of age is based on pharmacokinetic exposure and extrapolation of established efficacy of intravenous Orencia in polyarticular JIA patients and subcutaneous Orencia in patients with RA. *Safety and efficacy of Orencia ClickJect autoinjector for subcutaneous injection have not been studied in patients under 18 years of age. *Safety and efficacy in pediatric patients for uses other than juvenile idiopathic arthritis have not been established. *Adverse reactions were similar to those observed in adults. *Information on adverse reactions, immunogenicity, dosing, clinical trials. *Postmarketing study.
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B,P
Sponsor:
Bristol-Myers Squibb
Pediatric Exclusivity Granted Date:
02/17/2017
NNPS:
FALSE
Therapeutic Category:
Anti-inflammatory
-
-